Redeye comments on Scandion’s Q2‘21 report, following an eventful quarter. Towards the end of Q2, Scandion presented promising CORIST phase II dose-finding data. We are encouraged by the company’s progress and reiterate our Base Case at SEK 24 per share.
LÄS MER